|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:AstraZeneca
gptkb:CureVac
gptkb:Zymeworks
gptkb:Achillion_Pharmaceuticals
gptkb:Sangamo_Therapeutics
gptkb:Portola_Pharmaceuticals
gptkb:Syntimmune
gptkb:Dicerna_Pharmaceuticals
AstraZeneca's_rare_disease_unit
Wilson_Therapeutics
|
|
gptkbp:CEO
|
gptkb:David_Hallal
|
|
gptkbp:clinicalTrials
|
gptkb:ALXN1720
Phase 1
Phase 2
Phase 3
ALXN1210
ALXN1830
C5 complement inhibitor
ALXN1210 for CIDP
ALXN1210 for LUPUS
ALXN1210 for PNH
ALXN1210 for aHUS
ALXN1210 for gMG
ALXN1210_for_APS
ALXN1210_for_ITP
ALXN1210_for_MG
ALXN1210_for_MS
ALXN1210_for_NMOSD
ALXN1210_for_SLE
|
|
gptkbp:employees
|
approximately 3,000
|
|
gptkbp:focusArea
|
metabolic disorders
neurology
hematology
immunology
|
|
gptkbp:founded
|
1992
|
|
gptkbp:founder
|
gptkb:Leonard_Bell
|
|
gptkbp:headquarters
|
gptkb:Boston,_Massachusetts
gptkb:United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alexion Pharmaceuticals
|
|
gptkbp:notableEvent
|
Soliris
Ultomiris
|
|
gptkbp:partnerships
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Amgen
Sanofi
AbbVie
|
|
gptkbp:researchAndDevelopment
|
$500 million (2020)
|
|
gptkbp:revenue
|
$2.4 billion (2020)
|
|
gptkbp:specializesIn
|
rare diseases
|
|
gptkbp:stockSymbol
|
gptkb:ALXN
|
|
gptkbp:subsidiary
|
gptkb:Syntimmune
|
|
gptkbp:website
|
www.alexion.com
|